Neurocrine Biosciences (NBIX) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $146.38 +0.58%
EPS Growth %: -12.0%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
RBKB, ASBH, CMSG, More
EPS Growth %: -12.0%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
RBKB, ASBH, CMSG, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24).
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Gouverneur Bancorp, Inc. (GOVB) Tops Q4 EPS by 23c
- Sanofi (SNY) Tops Q3 EPS by 199c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
